← Leaderboards
Stephen Bernard
University Of North Carolina Chapel Hill
$2,912,053
Attributed
$2,912,053
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,912,053 · 3
By mechanism
M01$2,912,053 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Nancy E Thomas$10,693,117
- Mark Peifer$14,266,212
- Channing J Der$34,774,720
- William Hatfield Dow$11,779,196
- Alicja Bielawska$7,829,586
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyClinical ResearchHuman Therapy EvaluationHuman SubjectAntineoplasticsColorectal NeoplasmsCis Platinum CompoundDrug Screening /EvaluationEpinephrineInjection /InfusionLiver NeoplasmsMetastasisBiotransformationHuman MortalityCancer PreventionBreast NeoplasmsTamoxifenLongitudinal Human StudyClinical TrialsChemopreventionFemaleCancer Risk
Grant awards (16)
NSABP P-1--TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$190,747
M01 · FY2002 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$190,747
M01 · FY2002 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$190,747
M01 · FY2002 · RR
NSABP P-1--TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$294,555
M01 · FY2001 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$294,555
M01 · FY2001 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$294,555
M01 · FY2001 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$190,747
M01 · FY2001 · RR
NSABP P-1--TRIAL TO DETERMINE WORTH OF TAMOXIFEN FOR PREVENTING BREAST CANCER$190,747
M01 · FY2001 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$190,747
M01 · FY2001 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$294,555
M01 · FY2000 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$294,555
M01 · FY2000 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$294,555
M01 · FY2000 · RR
MX 405: INTRADOSE (CISPLATIN &EPINEPHRINE) INJECTABLE GEL$241
M01 · FY2000 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$0
M01 · FY2000 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$0
M01 · FY2000 · RR
BIOTRANSFORMATION PRODUCTS OF OXALIPLATIN COLORECTAL CANCER$0
M01 · FY2000 · RR